CYPHERPUNK TECHNOLOGIES INC. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
CYPHERPUNK TECHNOLOGIES INC. (CYPH) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $4.01 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-03-16
- CYPHERPUNK TECHNOLOGIES INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $4.01M, a 79.23% decline from fiscal 2024.
- CYPHERPUNK TECHNOLOGIES INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $19.31M.
- CYPHERPUNK TECHNOLOGIES INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2021 was $12.41M, a 23.29% increase from fiscal 2020.
- CYPHERPUNK TECHNOLOGIES INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2020 was $10.07M, a 23.84% decline from fiscal 2019.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|
| 2025-12-31 | $4.01M 10-K · filed 2026-03-16 |
| 2024-12-31 | $19.31M 10-K · filed 2026-03-16 |
| 2021-12-31 | $12.41M 10-K · filed 2022-03-11 |
| 2020-12-31 | $10.07M 10-K · filed 2022-03-11 |
| 2019-12-31 | $13.22M 10-K · filed 2021-03-12 |
| 2018-12-31 | $8.18M 10-K · filed 2020-03-16 |
| 2017-12-31 | $17.50M 10-K · filed 2019-04-01 |
| 2016-12-31 | $9.06M 10-K · filed 2018-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |